TY - JOUR
T1 - Optimal first-line treatment of chronic myeloid leukemia
T2 - How to use imatinib and what role for newer drugs?
AU - Jabbour, Elias
AU - Cortes, Jorge
AU - Kantarjian, Hagop
N1 - Copyright:
Copyright 2009 Elsevier B.V., All rights reserved.
PY - 2007/5
Y1 - 2007/5
N2 - The development of imatinib mesylate (Gleevec), a tyrosine kinase inhibitor targeted against the causative Bcr-Abl protein in chronic myeloid leukemia (CML), has resulted in hematologic and cytogenetic remissions in all phases of CML. Following imatinib treatment, more than 90% of patients obtain complete hematologic response, and 70% to 80% achieve a complete cytogenetic response. With 5 years of follow-up, the data are very encouraging, exhibiting a major change in the natural history of the disease. The understanding of at least some of the mechanisms of resistance to imatinib has led to a rapid development of new agents that may overcome this resistance. Combination strategies are currently being investigated in preliminary clinical studies and may prove to be useful. Overall, there are an increasing number of treatment options now available for patients with CML.
AB - The development of imatinib mesylate (Gleevec), a tyrosine kinase inhibitor targeted against the causative Bcr-Abl protein in chronic myeloid leukemia (CML), has resulted in hematologic and cytogenetic remissions in all phases of CML. Following imatinib treatment, more than 90% of patients obtain complete hematologic response, and 70% to 80% achieve a complete cytogenetic response. With 5 years of follow-up, the data are very encouraging, exhibiting a major change in the natural history of the disease. The understanding of at least some of the mechanisms of resistance to imatinib has led to a rapid development of new agents that may overcome this resistance. Combination strategies are currently being investigated in preliminary clinical studies and may prove to be useful. Overall, there are an increasing number of treatment options now available for patients with CML.
UR - http://www.scopus.com/inward/record.url?scp=34249940036&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34249940036&partnerID=8YFLogxK
M3 - Review article
C2 - 17564324
AN - SCOPUS:34249940036
SN - 0890-9091
VL - 21
SP - 653
EP - 662
JO - ONCOLOGY
JF - ONCOLOGY
IS - 6
ER -